Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progression

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is associated with a clinical spectrum ranging from asymptomatic carriers to critically ill patients with complications including thromboembolic events, myocardial injury, multisystemic inflammatory syndromes and death. Since the beginning of...

Descripción completa

Detalles Bibliográficos
Autores principales: Urwyler, Pascal, Moser, Stephan, Trendelenburg, Marten, Sendi, Parham, Osthoff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393183/
https://www.ncbi.nlm.nih.gov/pubmed/36030710
http://dx.doi.org/10.1016/j.molimm.2022.08.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393183/
https://www.ncbi.nlm.nih.gov/pubmed/36030710
http://dx.doi.org/10.1016/j.molimm.2022.08.008

Ejemplares similares